

PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026. Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and half year ended 30 September, 2020

		Standalone (Ind AS)							Consolidated (Ind AS)					
	Particulars (Refer notes below)	Quarter Ended 30-09-2020 (Unaudited)	Quarter Ended 30-06-2020 (Unaudited)	Quarter Ended 30-09-2019 (Unaudited)	Half Year Ended 30-09-2020 (Unaudited)	Half Year Ended 30-09-2019 (Unaudited)	Year Ended 31-03-2020 (Audited)	Quarter Ended 30-09-2020 (Unaudited)	Quarter Ended 30-06-2020 (Unaudited)	Quarter Ended 30-09-2019 (Unaudited)	Half Year Ended 30-09-2020 (Unaudited)	Half Year Ended 30-09-2019 (Unaudited)	Year Ended 31-03-2020 (Audited)	
1	Revenue from operations		2403600000000000000000000000000000000000	001/4/00000000000	6118000-00000000	200000000000000000000000000000000000000	25TTANDODE - 40TO	94001-1090 T-01090-12	20 7 M	AUCTOS VIAROUS ACTIO	3.20.000000000	5170417417470b C15	CONTRACTOR PRODUCT	
	(a) Net sales	20,254.92	16,524.45	17,426.23	36,779.37	31,978.56	64,912.00	29,081.18	23,092.83	27,637.31	52,174.01	50,473.35	103,972.28	
- /	(b) Other operating income	366.73	304.77	471.96	671.50	907.56	2,214.31	443.61	355.04	513.09	798.65	905.84	2,437.41	
	Total revenue from operations	20,621.65	16,829.22	17,898.19	37,450.87	32,886.12	67,126.31	29,524.79	23,447.87	28,150.40	52,972.66	51,379.19	106,409.69	
1	Other income	634.04	1,348.49	1,924.68	1,982.53	2,610.09	6,067.88	(318.81)	585.14	808.25	266.33	824.94	1,596.02	
11	Total income (I + II)	21,255.69	18,177.71	19,822.87	39,433.40	35,496.21	73,194.19	29,205.98	24,033.01	28,958.65	53,238.99	52,204.13	108,005.71	
/	Expenses	8	550	300	195	222	18	- 1	100	1/16	88	33%	- 33	
	(a) Cost of materials consumed	7,503.36	5,917.41	5,675.87	13,420.77	10,869.60	22,519.81	8,648.40	7,041.92	6,466.53	15,690.32	12,552.58	25,414.74	
- /	(b) Purchases of stock-in-trade	658.51	762.73	928.73	1,421.24	1,894.86	3,652.41	2,976.78	217.83	2,788.10	3,194.61	5,375.10	10,290.83	
	(c) Changes in inventories of finished goods,	100 (0000000000000000000000000000000000	100000000000	55555057(0)	25E47TH 2500220V	10.4 20.4 10.0 (O. 10	188 P.O. 27 (2002)	93014 0630200303.00	EDSE(201-020)/1	GETADITIONER	0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000	1896-00-00-00-00-00-00-00-00-00-00-00-00-00	X1040050000	
- /	work-in-progress and stock-in-trade	41.63	(157.24)	196.85	(115.61)	104.01	487.68	(1,218.03)	823.91	606.86	(394.12)	34.83	1,280.82	
- /	(d) Employee benefits expense	3,375.76	2,372.36	3,457.94	5,748.12	5,658.10	10,723.27	7,002.54	5,096.06	6,866.00	12,098.60	11,732.90	22,547.76	
	(e) Finance costs	604.12	599.38	651.67	1,203.50	1,332.43	2,563.90	806.32	937.40	897.71	1,743.72	1,827.86	3,773.18	
	(f) Depreciation, amortisation and impairment expense	367.94	358.09	333.22	726.03	654.87	1,385.38	1,040.65	1,132.22	941.61	2,172.87	1,848.92	4,171.66	
- /	(g) Other expenses	4,088.84	2,846.52	3,833.52	6,935.36	7,467.83	16,700.84	6,586.97	5,487.47	6,918.83	12,074.44	13,760.58	29,894.72	
	Total expenses (IV)	16,640.16	12,699.25	15,077.80	29,339.41	27,981.70	58,033.29	25,843.63	20,736.81	25,485.64	46,580.44	47,132.77	97,373.71	
1	Profit/(loss) before exceptional items and tax (III - IV)	4,615.53	5,478.46	4,745.07	10,093.99	7,514.51	15,160.90	3,362.35	3,296.20	3,473.01	6,658.55	5,071.36	10,632.00	
/1	Exceptional items (gain) (Refer note 6)	0.00	(279.90)	73714 Meves	(279.90)		(185.54)	(31.40)	(279.90)	-	(311.30)	***************************************	(328.76)	
n In	Profit/(loss) before tax (V - VI)	4,615.53	5,758.36	4,745.07	10,373.89	7,514.51	15,346.44	3,393.75	3,576.10	3,473.01	6,969.85	5,071.36	10,960.76	
Ш	Tax expense :	31010100	01100100	15.31110.10.7	10,0,0.00	1,103,1101	10,010,11	,0,000,11,0		2011/2001	0,000.00	0,011100	10,000.0	
	Current tax	802.53	1,012.33	713.19	1,814.86	1,317.96	2,692.37	1,367.28	1,322.78	1,030.15	2,690.06	1,989.77	3,961.27	
	Deferred tax	(215.76)	121.28	(288.04)	(94.48)	(401.80)	(891.41)	(313.46)	(287.10)	(112.56)	(600.56)	(566.64)	(760.21)	
X	Profit/(loss) for the period from continuing	(210.70)	15.000	(200.04)	(04.40)	(401.00)	(00 (.41)	(010.40)	(207.10)	(112.00)	(000.00)	(000.04)	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
· Second	operations (VII - VIII)	4,028.76	4,624.75	4,319.92	8,653.51	6,598.35	13,545.48	2,339.93	2,540.42	2,555.42	4,880.35	3,648.23	7,759.70	
	Profit/(loss) before tax from discontinuing operations	1,020.70	1,021,10	1,010.02	0,000.01	0,000.00	10,010.10	2,000.00	2,010.12	2,000.12	1,000.00	0,0,0,20	1,1,00.1,0	
CI.	Tax expense of discontinuing operations :		12.7	0,50	251	1,520		NAC.	5.2.2	=61	***			
	Current tax	250	20	543	20			596	3-3	19	10	20		
	Deferred tax		33		S 1					18	1 2	3 1		
aı	Profit/(loss) for the period from discontinuing	5.75	12.0		58			892	900	18	9	19		
ane.	operations (X - XI)	1727	26	1027	28	120	25	720	920	12	10	26	2	
111	Profit/(loss) for the period for continuing and													
	discontinuing operations (IX + XII)	4,028.76	4,624.75	4,319.92	8,653.51	6,598.35	13,545.48	2,339.93	2,540.42	2,555.42	4,880.35	3,648.23	7,759.70	
IV	Other comprehensive income	110000	1/10/2011/2011	1100000	515550000000000000000000000000000000000		10,010.10			ALIAR BALLO	0/0000000	2,00,000		
	A (i) Items that will not be reclassified to profit or loss	5.44	5.51	(43.72)	10.95	(25.69)	(88.83)	(137.89)	0.37	(164.35)	(137.52)	(202.60)	52.52	
- /	(ii) Income tax relating to items that will not be		30.01	(10.12)	1000000	(20.00)	(00.00)	(107.00)	83,034	(101.00)	(10/.02/	(202.00)	02.02	
	reclassified to profit or loss	(1.90)	(1.93)	14.04	(3.83)	8.47	34.61	15.72	(0.38)	29.86	15.34	31.08	15.08	
	B (i) Items that will be reclassified to profit or loss	11.000	7757880	7.77	(0,00)	1200	811.87	(291.15)	259.62	(947.49)	(31.53)	(535.39)	(2,248.33)	
- /	(ii) Income tax relating to items that will be			60%		10000		((Constant of the constant of	10/4-204-00/		(
- /	reclassified to profit or loss	1.00	400	(300)	92	0.00	81	215.22	(16.32)	(81.50)	198.90	(56.51)	(276.42)	
V	Total comprehensive income	4,032.30	4,628.33	4,290.24	8,660.63	6,581.13	13,491.26	2,141.83	2,783.71	1,391.94	4,925.54	2,884.81	5,302.55	
VI	Total comprehensive income attributable to:	ATTA SALSTAN	1050000000	920302005	200000000			380 TO SERVE TO A	(MINASAUSECOLD	200000000000000000000000000000000000000	0.0000000000000000000000000000000000000	3425333330	20,000,000	
	- Non-controlling interests							(0.43)	1.33	0.47	0.90	0.75	0.03	
- /	- Owners of the Company	4,032.30	4,628.33	4,290.24	8,660.63	6,581.13	13,491.26	2,142.26	2,782.38	1,391.47	4,924.64	2,884.06	5,302.52	
VII	Other equity	(2)	16	200	20		131,980.47			100		27	60,422.88	
	(of Re 1/- each) (not annualised)*		5000010000	2000000		W. CARROON			CONTRACTOR OF	-	1000000	1000000		
- /	Basic EPS (in Rupees)	14.28	16.39	15.31	30.67	23.38	48.00	8.29	9.00	9.06	17.30	12.93	27.50	
	Diluted EPS (in Rupees)	14.28	16.39	15.31	30.67	23.38	48.00	8.29	9.00	9.06	17.30	12.93	27.50	
X	Earning per share (EPS) (for discontinuing operations)	65/87/700	2,000,000	55,050	550000000	1,000,000,000		87,00000	8818050	80.00	2020 022	3,73,7,76	201.02.00	
-	(of Re 1/- each) (not annualised)*													
	Basic EPS (in Rupees)	1/4	20		48	40	22	100		92	82	25	2	
	Diluted EPS (in Rupees)	10*1				250	-	1,000		85				
x l	Earning per share (EPS) (for continuing and		===	1000	88	(252.)	#	10-64	952	893	188	- H	-	
	discontinuing operations)													
- /	(of Re 1/- each) (not annualised)*													
	Basic EPS (in Rupees)	14.28	16.39	15.31	30.67	23.38	48.00	8.29	9.00	9.06	17.30	12.93	27.50	
- 7	Diluted EPS (in Rupees)	14.28	16.39	15.31	30.67	23.38	48.00	8.29	9.00	9.06	17.30	12.93	27.50	

* except for the year ended 31 March 2020 Glenmark Pharmaceuticals Limited

Statement of assets and liabilities

Glenmark Pharmaceuticals Limited

Consolidated statement of cash flows for the half year ended 30 September, 2020 Statement of cash flows for the half year ended 30 September, 2020 (All amounts in million of Indian Rupees, unless otherwise stated)

Glenmark Pharmaceuticals Limited

(All amounts in million of Indian Rupees, unless otherwise stated)

	STAND	ALONE	CONSO	LIDATED
Particulars	Ind AS	Ind AS As at 31.03.2020 Audited	Ind AS	Ind AS
ASSETS				
Non current assets				
Property, plant and equipment	14,817.15	14,688.16	29,453.85	29,777.08
Capital work-in-progress	1,042.78	1,524.97	11,280.58	10,906.36
Goodwill	1,012.10	1,021.07	558.20	528.99
Other intangible assets	1,353.05	1,431.29	21,074.40	19,979.48
Intangible assets under development	1,468.05	475.17	1,681.87	1,312.50
Financial assets	1,400.00	475.17	1,001.07	1,012.00
(i) Investments	47,249.23	47,139.29	246.00	245.91
		\$12000000000000000000000000000000000000	240.00	245.91
(ii) Loans	76,617.02	71,155.46	740.00	055.70
(iii) Other financial assets	333.65	268.80	713.63	655.79
Deferred tax assets (net)	8,138.00	8,047.35	15,022.68	14,557.05
Other non-current assets	525.78	546.53	1,081.32	848.75
Total non- current assets	151,544.71	145,277.02	81,112.53	78,811.91
Current assets				
Inventories	8,097.11	8,375.02	22,025.01	21,356.24
Financial assets	Anna Carlo Arrico Constant	A-00-07 SEVERISHOOM	270.41.24.027.0007.00000	11 11 11 11 11 11 11 11 11 11 11 11 11
(i) Investments	19	-	89	
(ii) Trade receivables	20,454.24	18,352.40	26,479.90	24,089.62
(iii) Cash and cash equivalents	419.78	872.92	8,872.94	11,102.75
(iv) Bank balance other than cash	GER 10890902	1120,000000,001	0.00.0000000000000000000000000000000000	9/5/1/16/2/9/9/1920
and cash equivalents	8.24	9.67	8.24	9.67
(v) Other financial assets	10,747.91	11,191.99	1,398.12	1,249.44
Current tax assets	188131100	1.11.00.000		3000.000
Other current assets	5,872.05	5,436.97	11,018.42	10,228.44
Total current assets	45,599.33	44,238.97	69,802.63	68,036.16
Total assets	197,144.04	189,515.99	150,915.16	146,848.07
EQUITY AND LIABILITIES	101,111.01	100,010.00	100,010.10	110,010.07
Equity				
Equity share capital	282.17	282.17	282.17	282.17
Other equity	139,963.50	131,980.47	64,670.03	60,422.88
Non-controlling interests	133,303.30	131,300.47	(3.11)	(3.92)
Liabilities	100	27	(3.11)	(3.32)
1787 V V V V V V V V				
Non-current liabilities				
Financial liabilities	1051001	04.044.00	05 050 00	
(i) Borrowings	16,542.04	31,311.66	25,959.00	40,429.94
(ii) Other financial liabilities	1,960.20	2,056.51	4,332.44	4,288.01
Deferred tax liabilities (net)	15-	S-	196.82	164.48
Other non- current liabilities	-		7.76	4.68
Total non-current liabilities	18,502.24	33,368.17	30,496.02	44,887.11
Current liabilities				
Financial liabilities				
(i) Borrowings	3,627.16	4,425.97	3,627.16	4,425.97
(ii) Other financial liabilities	16,490.56	2,035.95	21,317.17	8,583.66
(iii) Trade payables				
- Total outstanding dues of Micro				
enterprises and Small enterprises	621.01	748.82	804.19	849.48
- Total outstanding dues of other than	300000	2,23,23	1000000	
Micro enterprises and Small enterprises	14,806.82	15,101.71	20,866.53	20,408.95
Other current liabilities	282.67	388.25	1,191.80	1,432.65
Provisions	1,769.42	1,024.04	6,491.32	5,151.99
Current tax liabilities (net)	798.49	160.44	1,171.88	407.13
Total current liabilities				
iotal current liabilities	38,396.13	23,885.18	55,470.05	41,259.83

Particulars		Half Year Ended 30-09-2019 (Unaudited)	Particulars	11.75 (C. 10.157), DOUGHTON, DESCRIPTION	Half Year Ended 30-09-2019 (Unaudited)	
(A) Cash flow from operating activities			A. Cash flow from operating activities			
Profit before tax	6,969.85	5,071.37	Profit before tax from			
Adjustments to reconcile profit before tax to net cash provided by operating activities:			- Continuing operations Adjustments for:	10,373.89	7,514.51	
Depreciation, impairment and amortisation	2,172.87	1,848.92	Depreciation and amortisation	726.03	654.87	
Finance costs	1,743.72	1,827.86	Finance costs	1,203.50		
Interest income	(9.70)	(27.76)	Interest income	(1,964.06)		
(Profit)/loss on sale of property, plant and equipments	26.18	(1.13)	Loss on sale of Property, plant and equipments	6.30	1.81	
Fair valuation of Investment	(0.09)	(1.10)	Employee share based compensation expense	27.81	22.37	
Employee benefit obligation	407.59	197.96	Fair valuation of Investment	(0.09)		
Provision for doubtful debts / expected credit losses	0.09	100.14	Provision for bad and doubtful debts/	1.3.5555.7X		
Employee share based compensation expense	27.81	22.37	expected credit losses	82	100.00	
	300000000000000000000000000000000000000	22.31	Provision for gratuity and compensated absence	118.78	95.58	
Exceptional item	(311.30)	(000 00)	Exceptional item	(279.90)	200000	
Unrealised foreign exchange (gain)	(245.89)	(208.32)	Unrealised foreign exchange (gain)	2,076.00	(287.84)	
Operating profit before working capital changes	10,781.13	8,831.41	Operating profit before working		1802236236	
Changes in operating assets and liabilities	(0.00 (.00)		capital changes	12,288.26	8,024.35	
- (Increase)/ Decrease in trade receivables	(2,334.88)	869.82	Adjustments for changes in working capital:	ASSESSED ON THE PARTY OF	100000 MODEL	
- (Increase) / Decrease in inventories	(321.72)	800.66	 (Increase)/ Decrease in trade receivables 	(2,666.37)	3,621.35	
- (Increase)/ Decrease in other assets	(1,402.41)	(816.83)	 (Increase) / Decrease in other receivables 	(238.89)	(193.40)	
Increase/(Decrease) in trade payable and	(E07.0E)	/4 700 60	- (Increase)/ Decrease in inventories	277.91	1,202.03	
other liabilities	(537.85)	(1,728.63)	 Increase / (Decrease) in trade and other payables 	(542.79)	(676.81)	
Cash generated from operations	6,184.27	7,956.43	Cash generated from operations	:	11,977.52	
Income taxes paid	(1,945.27)	(2,089.47)	- Taxes paid (net of refunds)	The second second second second	(1,556.05)	
Net cash generated from operating activities	4,239.00	5,866.96	Net cash generated from operating activities	7,941.31	10,421.47	
(B) Cash flow from investing activities			B. Cash flow from investing activities			
(Increase)/ Decrease in restricted cash	1.39	707.74	Purchase of Property, plant and equipment and			
Interest received Payments for Purchase of Property, plant and equipment and Intangible assets (including Capital work in progress)	13.90	29.32 (5,122.75)	Intangible assets (including Capital work in progress) Proceeds from sale of Property,plant and equipment, Intangible assets and business	(1,442.48)	(665.26)	
Proceeds from sale of Property,plant and	(4,155.75)	(0,122.75)	(disclosed as exceptional item)	338.54	0.52	
equipment, Intangible assets and brands, business (disclosed as exceptional item)	425.82	208.45	Loans to subsidiaries (net)		(14,243.67	
Net cash used in investing activities		(4,177.24)	(Increase)/decrease in bank deposits and margin money	1.43	37.99	
(C) Cash flow from financing activities	(0,7 10.04)	(4,177.24)	Share application money paid	(26.29)	(136.97)	
Proceeds from long-term borrowings	1,719.71	2,096.70	Interest received	2,823.29		
Repayments of long-term borrowings	(2,430.03)	(2,620.88)	Net cash used in investing activities		(11,640.00)	
Proceeds from /(repayment) of short-term borrowings (net)	(560.62)	1,128.91	C. Cash flow from financing activities Proceeds from short-term borrowings (net)	(560.62)	791.26	
Interest paid	(1,271.46)	(1,561.41)	Interest paid	(781.76)	(905.44)	
Payment of lease liabilities	(464.72)	(219.46)	Dividend paid (including dividend distribution tax)	(1.43)	(2.42)	
Dividend paid (including tax on dividend)	(1.43)	(2.42)	Payment of lease liability	(145.01)	(65.40)	
			Net cash used in financing activities	(1,488.82)	(182.00)	
Net cash used in financing activities Effect of exchange rate changes on cash and	(3,008.55)	*. *	Net (decrease) / increase in cash and cash equivalents	(*) (*) (*) (*) (*) (*) (*) (*) (*) (*)	(1,400.53)	
cash equivalents Net increase/(decrease) in cash and cash equivalents	258.38 (2,229.81)	(710.43) (199.27)	Opening balance of cash and cash equivalents Exchange fluctuation on cash	872.92	10.5	
Opening balance of cash and cash equivalents	11,102.75	9,362.78	and cash equivalent	0.45	(0.47)	
Closing balance of cash and cash equivalents		3520	Closing balance of cash and cash equivalents	419.78	1	
Closing balance of cash and cash equivalents	8,872.94	9,163.51	oroung buildies of sasif and sasif equivalents	110.10	1,140.07	

Total equity and liabilities

Total liabilities

1 The Financial results have been prepared in accordance with Indian Accounting Standards (Ind AS') prescribed under Section 133 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.

2 The above results were reviewed by the Audit Committee at its meeting held on 5th November, 2020 and approved by the Board of Directors at their meeting held on 6th November, 2020. 3 The results for the quarter and half year ended 30th September, 2020 presented were subjected to a 'Limited Review' by statutory auditors of the Company who have issued an unmodified report on the said results.

86,146.94

146,848.07

85.966.07

150,915.16

4 Pursuant to the Taxation Laws (Amendment) Ordinance 2019 ('Ordinance') Issued by Ministry of Law and Justice (Legislative Department) on 20th September 2019 which is effective 1st April 2019, domestic companies have the option to pay corporate Income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Ordinance has subsequently been enacted as Taxation Laws (Amendment) Act, 2019. The Company upon the amendment made an assessment of the Impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit and other exemptions. The Company has also re-measured its deferred tax liability following the clarification issued by Technical Implementation Committee by applying the lower tax rate in measurement of deferred taxes only to extent that the deferred tax liabilities are expected to be reversed in the period during which it expects to be subject to lower tax rate. 5 The Company completed its sale of intimate hygiene brand, VWash to Hindustan Unilever Limited during the quarter ended 30th June, 2020.

6 "Exceptional item: Exceptional items in the standalone financial results for the quarter and half year ended 30th September, 2020 of Rs. Nil and Rs.279.90 respectively and in the consolidated financial results for the quarter and half year ended 30th September, 2020 of Rs. 31.40 and Rs. 311.30 respectively are on account of gain from transfer of intimate hygiene brand Vwash, sale of IP assets and reimbursement of onetime costs." 7 The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are notified.

8 The list of subsidiaries as of 30th September, 2020 is provided in Annexure A. 9 The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e.,

10 As at 30th September, 2020, pursuant to Employee Stock Options Scheme 2016, 404,247 options were outstanding, which upon exercise are convertible into equivalent number of equity shares. 11 The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Group's financial results for the guarter and half year ended 30th September,

12 Diluted EPS has been computed considering the effect of conversion of ESOPs. 13 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

56,898.37

197,144.04

Glenmark Pharmaceuticals Limited

Annexure A List of entities included in the consolidated financial results for the quarter and half year ended 30 September 2020

57,253.35

189.515.99

1.Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2.Glenmark Pharmaceuticals S.R.O.4.Glenmark Phar Pharmaceuticals S.R.L. (liquidated with effect from 30 July 2020) 8. Glenmark Pharmaceuticals Inc. 10. Glenmark Pharmaceuticals Inc. 11. Glenmark Pharmaceuticals S.P. z.o.o. 9. Glenmark Pharmaceuticals Inc. 10. Glenmark Pharmaceuticals Inc. 11. Pharmaceuticals Peru SAC 15. Glenmark Pharmaceuticals Colombia SAS, Colo 22. Glenmark Philippines Inc. 23. Glenmark Pharmaceuticals (Nigeria) Ltd 24. Glenmark Pharmaceuticals (Australia) Pty Ltd 26. Glenmark Pharmaceuticals (Opty) Ltd 27. Glenmark Pharmaceuticals (Nigeria) Ltd 24. Glenmark Pharmaceuticals (Nigeria) Ltd 26. Glenmark Pharmaceuticals (Nigeria) Ltd 27. Glenmark Pharmaceuticals (Nigeria) Ltd 28. Glenmark Pharmaceuticals (Nigeria) Ltd 28. Glenmark Pharmaceuticals (Nigeria) Ltd 29. Glenmark Pharmaceuticals (Niger Co. Ltd 29.Glenmark Pharmaceuticals B.V. 30.Glenmark Pharmaceuticals Canada Inc. 32.Glenmark Pharmaceuticals Canada Inc. 32.Gl 36. Glenmark Pharmaceuticals Distribution s.r.o. 37. Glenmark Pharmaceuticals Singapore Pte. Ltd. 41. Ichnos Sciences Biotherapeutics SA (Formerly known as Glenmark Biotherapeutics SA) 42.Ichnos Sciences Inc., USA (w.e.f. 31 May, 2019) 43.Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited) 44.Glenmark Distribuidora De Medicamentos E Produtos Cosmeticos Ltda. (w.e.f. 20 March 2020)

> For and on behalf of the Board of Directors Glenn Saldanha Chairman & Managing Director

Mumbai, November 6, 2020

financialexp.epapr.in



PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and half year ended 30 September, 2020

International Control of Market Finded Mar	Bestlevitere	Standalone (Ind AS)							Consolidated (Ind AS)					
(a) Net sake (b) Chromogening ricome (c) Other operating ricome (c) Other o	(Refer notes below)	30-09-2020	30-06-2020	30-09-2019	30-09-2020	30-09-2019	31-03-2020	30-09-2020	30-06-2020	30-09-2019	30-09-2020	30-09-2019	Year Ended 31-03-2020 (Audited)	
(b) Other operating income 366,73 304,77 471,96 671,50 907,56 2,214,31 44,361 355,04 512,09 798,65 905,84 1034,190,190,190,190,190,190,190,190,190,190	Revenue from operations		0		1									
Total revenue from Operations 20.621.65 16,829.32 17,986.13 37,450.87 32,886.12 67,128.31 29,524.79 23,447.87 28,150.40 52,972.66 31,797.19 19,20.66 19,20.75 19,20.66 19,20.75 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67 19,20.67	(a) Net sales	20,254.92	16,524.45	17,426.23	36,779.37	31,978.56	64,912.00	29,081.18	23,092.83	27,637.31	52,174.01	50,473.35	103,972.28	
Total reversite from Speratorions 20,821,65 16,829,322 17,989,139 37,450,87 32,888,12 67,128,31 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23,447,87 23	(b) Other operating income				671.50	907.56	2,214.31						2,437.41	
Other income													106,409.69	
Total income (1+ II)													1,596.02	
Expenses													108,005.71	
(a) Cost of materials consumed (b) Purchases of stock-in-frade (c) Changes in inventiones of stock-in-frade (c) Changes in inventions of stock-in-frade (c) Changes in inv	50 T (40T) 100T) T (47T) (41T) (41T) (41T)	SHOWN SERVICES	1991.17.11.11	1373	***************	100000000000000000000000000000000000000	1.0110.1110	301800000	(90.01.900.01.01.01	M. C.		200000000000000000000000000000000000000		
(b) Purchases of stock-in-trade (C) Changes in immediates of finished goods, 41 (8) (157.2a) 198.85 (157.2b) (1		7 503 36	5 917 41	5 675 87	13 420 77	10.869.60	22 519 81	8 648 40	7 041 92	6 466 53	15 690 32	12 552 58	25,414.74	
(c) Changes in inventions of finished goods, work-in-projects and stock-in-frace (1) Employee benefits expense (3) 375.77 2,372.33 3,654.72 3,783.12 3,656.70 1,782.27 7,783.20 3,783.72 2,372.33 3,783.72 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.77 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.27 2,372.33 3,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.23 2,375.2					2004 T MAN 2010 C T T C T C T C T C T C T C T C T C T	200 M 200 E 200 E 200 E 200 E 200 E							10,290.83	
work-in-progress and stock-in-trade 41.63 (157.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65 (175.24) 156.65		000.01	102.70	320.70	1,761,67	1,004.00	0,002.41	2,070.70	217.00	2,700.10	0,104,01	0,070.10	10,230.00	
(id) Employee breefits expense (e) Finance contribution c	work-in-progress and stock-in-trade	41.63	(157.24)	196.85	(115.61)	104.01	487 68	(1.218.03)	823.91	606.86	(394.12)	34.83	1,280.82	
(e) Finance costs (f) Depresions, amortisation and impairment expense (f) Depresions													22,547.76	
0 Depreciation, amortisation and impairment expense (p) Other expenses (p) Other expens													3,773.18	
(g) Other expenses (h) 4,088.84 (180.00 to the period from continuing operations (h) VIII) (180.00 to the period from continuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontinuing operations (h) VIII) (180.00 to the period from discontin										100000000000000000000000000000000000000			4,171.66	
Total expenses (IV)													29,894.72	
Proff(()0ss) before exceptional items and tax (III-IV)														
Exceptional Items (gain) (Refer note 6)													97,373.71	
Profit/(loss) before tax (V - VI)				4,745.07		7,514,51				3,473.01	50 - 30 - 50 - 50 - 50 - 50 - 50 - 50 -	5,071.36	10,632.00	
Tax expenses: Current tax Bo2.53 1,012.33 713.19 1,814.86 1,317.96 2,692.37 1,367.28 1,322.78 1,030.15 2,690.06 1,989.77									A. W. C.			- The same 1	(328.76)	
Current tax Deferred tax Current tax Deferred tax Current tax	2011 100 (40 Cg) N 40 (40 Cg) Cg (40 C	4,615.53	5,758.36	4,745.07	10,373.89	7,514.51	15,346.44	3,393.75	3,576.10	3,473.01	6,969.85	5,071.36	10,960.76	
Deferred tax Profit (jobs) for the period from continuing operations (VII - VIII) (J12.56) (E00.56)	SOLUME DE SECTION DE LA CONTRACTOR DE LA	70,700,000,000	100000000000000000000000000000000000000	1120727721	000000000000000000000000000000000000000	22012222220	4202020203	0.0000000000000000000000000000000000000	N/1000000000	51000.01001	121107232308611	000102020000000	IF400000000000	
Profit/(loss) for the period from continuing operations 4,028.76 4,624.75 4,319.92 8,653.51 6,598.35 13,545.48 2,339.93 2,540.42 2,555.42 4,880.35 3,648.23					50 M to 2000 to 0.00 m to 0.00 m	5 PK 5 C F F F F F F F F F F F F F F F F F F							3,961.27	
Comparations (VII - VIII) Comparations Compar		(215.76)	121.28	(288.04)	(94.48)	(401.80)	(891.41)	(313.46)	(287.10)	(112.56)	(600.56)	(566.64)	(760.21)	
Control (Noss) before tax from discontinuing operations of tax expense of discontinuing operations of tax expense of discontinuing operations of tax expense of discontinuing operations (X - XI)		0.35/1/30/00/00/46/	12/2007/14		IN CONTROL OF THE PROPERTY OF	254.775425 104.75001		1999/06/07/64/07	285-28-00-017-30-60-0	2001020000000000	000000000000000000000000000000000000000	120000000000000000000000000000000000000		
Tax expense of discontinuing operations : Current tax Deferred tax Deferred tax Profit/(loss) for the period from discontinuing and discontinuing operations (X - XI) Profit/(loss) for the period for continuing and discontinuing operations (X - XI) Profit/(loss) for the period for continuing and discontinuing operations (X - XI) Other comprehensive income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to Items that will not be readssified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss		4,028.76	4,624.75	4,319.92	8,653.51	6,598.35	13,545.48	2,339.93	2,540.42	2,555.42	4,880.35	3,648.23	7,759.70	
Current tax Deferred tax Deferr	Profit/(loss) before tax from discontinuing operations	3	A.TVC.TSCALICATE	0.000.000.000.000.000.000.000.000.000.		570000000000000000000000000000000000000	500		**************************************		U. WOLSON 250	5.440.000.000.000	*	
Deferred tax Profit/(loss) for the period from discontinuing operations (X - XI) Profit/(loss) for the period for continuing and discontinuing operations (X - XI) Profit/(loss) for the period for continuing and discontinuing operations (IX + XII) 4,028.76 4,624.75 4,319.92 8,653.51 6,598.35 13,545.48 2,339.93 2,540.42 2,555.42 4,880.35 3,648.23 4,880.35 3,648.23 4,880.35 3,648.23 4,880.35 3,648.23 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.35 4,880.	Tax expense of discontinuing operations :													
Profit(loss) for the period from discontinuing operations (X - XI) Profit(loss) for the period for continuing and discontinuing operations (X - XI) 4,028.76 4,624.75 4,319.92 8,653.51 6,598.35 13,545.48 2,339.93 2,540.42 2,555.42 4,880.35 3,648.23 Volter comprehensive income A (i) literis that will not be reclassified to profit or loss (iii) Income tax relating to items that will not be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax rel			38		290	3+3	90	(*)			- 8	(19)		
Operations (X - XI) Profit (loss) for the period for continuing and discontinuing operations (IX + XII) 4,028.76 4,624.75 4,319.92 8,653.51 6,598.35 13,545.48 2,339.93 2,540.42 2,555.42 4,880.35 3,648.23	Deferred tax								- 3		9 1			
Operations (X - XI) Profit (Joss) for the period for continuing and discontinuing operations (IX + XII) 4,028.76 4,624.75 4,319.92 8,653.51 6,598.35 13,545.48 2,339.93 2,540.42 2,555.42 4,880.35 3,648.23		- 8	800		8570			0.00	900	(75)	50.	1997		
Il Profit/(loss) for the period for continuing and discontinuing operations (X + XII)	operations (X - XI)	-	2	12	20	257	2	(25)	2.	-		157	102	
discontinuing operations (IX + XII) 4,028.76 4,624.75 4,319.92 8,653.51 6,598.35 13,545.48 2,339.93 2,540.42 2,555.42 4,880.35 3,648.23	II Profit/(loss) for the period for continuing and		61		000				50		100	1000		
Volter comprehensive income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to Items that will not be reclassified to profit or loss (ii) Income tax relating to Items that will not be reclassified to profit or loss (ii) Income tax relating to Items that will not be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (291.15) 259.62 (947.49) (31.53) (555.39) (56.51) (15.72 (0.38) 34.69 (15.72 (16.32) (81.50) 198.90 (56.51) (17.02 (16.32) (81.50) 198.90 (56.51) (17.03 (18.72 (19.15) 12.52 (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32) (16.32)	discontinuing operations (IX + XII)	4,028.76	4.624.75	4,319.92	8,653.51	6,598.35	13,545.48	2,339.93	2,540.42	2,555.42	4,880.35	3.648.23	7,759.70	
A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to Items that will not be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (ii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (iii) Income tax relating to Items that will be reclassified to profit or loss (Items that will be reclassified to profit or loss (Items that will be reclassified to pro		200000000000000000000000000000000000000	F018/18/00/00 (015)		0.300,000,000				251.75 A.75022.15	\$100 MARKETS	(15)((3)(3)(3)(3)	450 700 000000	125 O.P. (2) (2) (2)	
(ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Income tax relating to items that will be reclassified to profit or loss B (i) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss V Total comprehensive income 1 Total comprehensive income attributable to: - Non-controlling interests - Owners of the Company 1 Other equity V Total company 1 Other equity 1 Other equity V Total compensive income attributable to: - Non-controlling interests - Owners of the Company 1 Other equity V Total components of the Company 1 Other equity 1 Other equity V Total components of the Company 2 Owners of the Company 3 Owners of the Company 4 Oy32.30 5 Oy		5.44	5.51	(43.72)	10.95	(25.69)	(88.83)	(137.89)	0.37	(164.35)	(137.52)	(202.60)	52.52	
reclassified to profit or loss (1.90) (1.93) 14.04 (3.83) 8.47 34.61 15.72 (0.38) 29.66 15.34 (31.08) (61.90) (ii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (1.90) (iii) Income tax relating to items that will be reclassified to profit or loss (35.39) (535.39) (535.39) (1.90) (iii) Income tax relating to items that will be reclassified to profit or loss (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2.91.15) (2000	313.1	(A) 50 (A)	1807.50	(40),000	100.00)	1,5,1,5,5	(,00000)	(1.01.00)	3/10/10/07	1	00.00	
B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (215.22 (16.32) (81.50) 198.90 (56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.56.51) (7.5		(1.90)	(1.93)	14.04	(3.83)	8.47	34.61	15.72	(0.38)	29.86	15.34	31.08	15.08	
(ii) Income tax relating to items that will be reclassified to profit or loss reclassified to		(1.55)	(1.00)	11.7.0	(0.00)								(2,248.33)	
reclassified to profit or loss Total comprehensive income VI Total comprehensive income attributable to: - Non-controlling interests - Owners of the Company VI Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) IX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) IX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) IX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) IX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) IX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) IX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) IX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees)					100000			(251.10)	200.02	(0-1110)	(01.00)	(000.00)	(2,210.00)	
Variable Total comprehensive income Total comprehensive income A,032.30 A,628.33 A,290.24 B,660.63 G,581.13 13,491.26 2,141.83 2,783.71 1,391.94 A,925.54 2,884.81	reclassified to profit or loss		Sw.	14	190	1990	40	215.22	(16.32)	(81.50)	198.90	(56.51)	(276.42)	
Total comprehensive income attributable to: Non-controlling interests 1.33 0.47 0.90 0.75 Owners of the Company 4,032.30 4,628.33 4,290.24 8,660.63 6,581.13 13,491.26 2,142.26 2,782.38 1,391.47 4,924.64 2,884.06 Other equity Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93 Diluted EPS (in Rupees) 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93 Saic EPS (in Rupees) 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93 Diluted EPS (in Rupees) 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93 Diluted EPS (in Rupees) 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93 Company 1.33 0.47 0.90 0.75 0.90 0.75 0.90 0.75 0.90 0.90 0.75 0.90 0.90 0.75 0.90 0.90 0.75 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90		4 032 30	4 628 33	4 290 24	8 660 63	6 581 13	13 491 26						5,302.55	
- Non-controlling interests - Owners of the Company -		4,002.00	4,020.00	7,200.27	0,000.00	0,001.10	10,401.20	2,141.00	2,700.71	1,001.04	4,020.04	2,004.01	0,002.00	
Owners of the Company Other equity Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Diluted EPS (in Rupees) Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Diluted EPS (in Rupees) Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Diluted EPS (in Rupees)	THE STATE OF THE S	_						(0.43)	1 33	0.47	0.90	0.75	0.03	
Other equity Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Diluted EPS (in Rupees) Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)* Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Diluted EPS (in Rupees) Diluted EPS (in Rupees)		4 022 20	68	4 200 24	0 660 63					10.000000000000000000000000000000000000			5,302.52	
Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees)		4,032.30		4,290.24		0,001.10		2,142.20	2,702,30	5.54500 11000	4,924.04	2,004.00		
(of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Diluted EPS (in Rupees) Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Diluted EPS (in Rupees) In a continuing operations operations operations operations of the continuing operations operations operations of the continuing operations operations operations operations of the continuing operations ope				17	350	872	131,980.47	8.73	50	87		1.50	60,422.88	
Basic EPS (in Rupees) 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93 14.28 16.39 15.31 30.67 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 23.38 2														
Diluted EPS (in Rupees) 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93 14.28 16.39 15.31 16.39 15.31 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39 16.39		200		000000000			199199	000000				178788		
X Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Diluted EPS (in Rupees)													27.50	
(of Re 1/- each) (not annualised)* Basic EPS (in Rupees) Diluted EPS (in Rupees)		14.28	16.39	15.31	30.67	23.38	48.00	8.29	9.00	9.06	17.30	12.93	27.50	
Basic EPS (in Rupees) Diluted EPS (in Rupees)														
Diluted EPS (in Rupees)														
Diluted EPS (in Rupees)			15	170	10207	0.00	50	1.77	51	U(2)	80	(31.67)	0.7	
			80	1	120		2		<u> </u>				32	
	Earning per share (EPS) (for continuing and													
discontinuing operations)														
(of Re 1/- each) (not annualised)*														
Basic EPS (in Rupees) 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93		14.28	16.39	15.31	30.67	23.38	48.00	8.29	9.00	9.06	17.30	12.93	27.50	
Diluted EPS (in Rupees) 14.28 16.39 15.31 30.67 23.38 48.00 8.29 9.00 9.06 17.30 12.93													27.50	

* except for the year ended 31 March 2020 Glenmark Pharmaceuticals Limited

Statement of assets and liabilities

Glenmark Pharmaceuticals Limited

Consolidated statement of cash flows for the half year ended 30 September, 2020 Statement of cash flows for the half year ended 30 September, 2020

Glenmark Pharmaceuticals Limited

	STANDALONE CONSOLIDATED			LIDATED		Half Year Half Year				Half Year
Particulars	Ind AS Ind AS Ind AS		Particulars	Ended	Ended 30-09-2019	Particulars	Ended 30-09-2020	Ended		
rainodais	As at 30.09.2020 As at 31.03.2020 As at 30.09.2020 As at 31.03.2020 Unaudited Unaudited Audited			As at 31.03.2020 Audited		The second secon	(Unaudited)	0.0000000000000000000000000000000000000	(Unaudited)	
ASSETS	*	49440000	- U-SANDONNON 19	-	(A) Cash flow from operating activities			A. Cash flow from operating activities	200	
Non current assets					Profit before tax	6,969.85	5,071.37	Profit before tax from		
Property, plant and equipment	14,817.15	14,688.16	29,453.85	29,777.08		0,000.00	3,071.07	- Continuing operations	10,373.89	7,514.5
Capital work-in-progress	1,042.78	1,524.97	11,280.58	10,906.36	Adjustments to reconcile profit before tax to				10,373.09	7,514.5
Goodwill			558.20	528.99	net cash provided by operating activities:	0 470 07	1 010 00	Adjustments for:		
Other intangible assets	1,353.05	1,431.29	21,074.40	19,979.48	Depreciation, impairment and amortisation	2,172.87	1,848.92	Depreciation and amortisation	726.03	
Intangible assets under development	1,468.05	475.17	1,681.87	1,312.50	Finance costs	1,743.72	1,827.86	Finance costs	1,203.50	
Financial assets	2.1/20/200000	01000003	W40874584	With the East	Interest income	(9.70)	(27.76)	Interest income	(1,964.06)	(1,409.38
(i) Investments	47,249.23	47,139.29	246.00	245.91	(Profit)/loss on sale of property, plant and equipments	26.18	(1.13)	Loss on sale of Property, plant and equipments	6.30	1.8
(ii) Loans	76,617.02	71,155.46	-	-	Fair valuation of Investment	(0.09)		Employee share based compensation expense	27.81	22.37
(iii) Other financial assets	333.65	268.80	713.63	655.79	Employee benefit obligation	407.59	197.96	Fair valuation of Investment	(0.09)	34.00.00
Deferred tax assets (net)	8,138.00	8,047.35	15,022.68	14,557.05		194600000		Provision for bad and doubtful debts/	0.000000	
Other non-current assets	525.78	546.53	1,081.32	848.75	Provision for doubtful debts / expected credit losses	0.09	100.14	expected credit losses	82	100.00
Total non- current assets	151,544.71	145,277.02	81,112.53	78,811.91	Employee share based compensation expense	27.81	22.37	Provision for gratuity and compensated absence	118.78	1000000000000
Current assets					Exceptional item	(311.30)	32	[] [] [] [] [] [] [] [] [] [] [] [] [] [N. H. C.	20.0200.00
Inventories	8,097.11	8,375.02	22,025.01	21,356.24	Unrealised foreign exchange (gain)	(245.89)	(208.32)	Exceptional item	(279.90)	1
Financial assets		575056555	New York Control (1991)		Operating profit before working capital changes	10,781.13	8,831.41	Unrealised foreign exchange (gain)	2,076.00	(287.84
(i) Investments	(SE)	40	91	20	Changes in operating assets and liabilities	1750,7004072	55435534514	Operating profit before working		2-2000-00
(ii) Trade receivables	20,454.24	18,352.40	26,479.90	24,089.62		(0.004.00)	000.00	capital changes	12,288.26	8,024.35
(iii) Cash and cash equivalents	419.78	872.92	8,872.94	11,102.75	(Increase)/ Decrease in trade receivables	(2,334.88)	869.82	Adjustments for changes in working capital:	520-00-00-00-00	50000000
(iv) Bank balance other than cash	RELIVED SATES.	25-12/02/5070	A 8 0 C 100 00 0 C 10	(Cottine of Contraction)	- (Increase) / Decrease in inventories	(321.72)	800.66	- (Increase)/ Decrease in trade receivables	(2,666.37)	3,621.35
and cash equivalents	8.24	9.67	8.24	9.67	 (Increase)/ Decrease in other assets 	(1,402.41)	(816.83)	- (Increase) / Decrease in other receivables	(238.89)	(193.40
(v) Other financial assets	10,747.91	11,191.99	1,398.12	1,249.44	- Increase/(Decrease) in trade payable and			- (Increase)/ Decrease in inventories	277.91	1,202.03
Current tax assets	COMIC	***	*	*:	other liabilities	(537.85)	(1,728.63)	- Increase / (Decrease) in trade and other payables	(542.79)	(676.81
Other current assets	5,872.05	5,436.97	11,018.42	10,228.44	Cash generated from operations	6,184.27	7,956.43	Cash generated from operations		11,977.52
Total current assets	45,599.33	44,238.97	69,802.63	68,036.16	Income taxes paid		(2,089.47)	- Taxes paid (net of refunds)		Service Services
Total assets	197,144.04	189,515.99	150,915.16	146,848.07	Net cash generated from operating activities	4,239.00	5,866.96			(1,556.05
EQUITY AND LIABILITIES	2 - 20 - 2			102		4,239.00	3,000.90	Net cash generated from operating activities	7,941.31	10,421.47
Equity					(B) Cash flow from investing activities	1027200	10000000	B. Cash flow from investing activities		
Equity share capital	282.17	282.17	282.17	282.17	(Increase)/ Decrease in restricted cash	1.39	707.74	Purchase of Property, plant and equipment and		
Other equity	139,963.50	131,980.47	64,670.03	60,422.88	Interest received	13.90	29.32	Intangible assets		05000000000000
Non-controlling interests	3.30° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00° 3.00°	#0	(3.11)	(3.92)	Payments for Purchase of Property, plant and			(including Capital work in progress)	(1,442.48)	(665.26
Liabilities			203 55	82 85	equipment and Intangible assets			Proceeds from sale of Property, plant and		
Non-current liabilities					(including Capital work in progress)	(4,159.75)	(5,122.75)	equipment, Intangible assets and business		
Financial liabilities					Proceeds from sale of Property, plant and			(disclosed as exceptional item)	338.54	0.52
(i) Borrowings	16,542.04	31,311.66	25,959.00	40,429.94	equipment, Intangible assets and brands,	200000000000000000000000000000000000000	POS 0901000	Loans to subsidiaries (net)	(8,600.57)	(14,243.67
(ii) Other financial liabilities	1,960.20	2,056.51	4,332.44	4,288.01	business (disclosed as exceptional item)	425.82	208.45	(Increase)/decrease in bank deposits and		A.C. M. Carrio e-cons.
Deferred tax liabilities (net)			196.82	164.48	Net cash used in investing activities	(3,718.64)	(4,177.24)	margin money	1.43	37.99
Other non- current liabilities	23723	-20	7.76	4.68	(C) Cash flow from financing activities	10000	10000 20	Share application money paid	(26.29)	(136.97
Total non-current liabilities	18,502.24	33,368.17	30,496.02	44,887.11	Proceeds from long-term borrowings	1,719.71	2,096.70	Interest received	2,823.29	\$5. N. E. W. S.
Current liabilities	111111111111111111111111111111111111111							Net cash used in investing activities	(6,906.08)	
Financial liabilities	0.2000000000000000000000000000000000000		AND RESIDENCE AND ADDRESS.	401000000000000000	Repayments of long-term borrowings	(2,430.03)	(2,620.88)	[(0,900.00)	(11,040.00
(i) Borrowings	3,627.16	4,425.97	3,627.16	4,425.97	Proceeds from /(repayment) of short-term	(500.00)	4 400 04	C. Cash flow from financing activities	/500.00	704.04
(ii) Other financial liabilities	16,490.56	2,035.95	21,317.17	8,583.66	borrowings (net)	(560.62)	1,128.91	Proceeds from short-term borrowings (net)	(560.62)	791.26
(iii) Trade payables					Interest paid	(1,271.46)	(1,561.41)	Interest paid	(781.76)	\$3000 D.C. 1000 C.
 Total outstanding dues of Micro 	1000500	0.0000000000000000000000000000000000000	800000000	88887787555	Payment of lease liabilities	(464.72)	(219.46)	Dividend paid (including dividend distribution tax)	(1.43)	(2.42
enterprises and Small enterprises	621.01	748.82	804.19	849.48	Dividend paid (including tax on dividend)	(1.43)	(2.42)	Payment of lease liability	(145.01)	(65.40
 Total outstanding dues of other than 		000000000000000000000000000000000000000	114 11117	350000000000000000000000000000000000000	Net cash used in financing activities	100000000000000000000000000000000000000	(1,178.56)	Net cash used in financing activities	(1,488.82)	(182.00
Micro enterprises and Small enterprises	14,806.82	15,101.71	20,866.53	20,408.95	Effect of exchange rate changes on cash and	(-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Net (decrease) / increase in cash and		######################################
Other current liabilities	282.67	388.25	1,191.80	1,432.65	cash equivalents	258.38	(710.43)	cash equivalents	(453.59)	(1,400.53
Provisions	1,769.42	1,024.04	6,491.32	5,151.99		200.00	(2 10.40)	Opening balance of cash and cash equivalents	872.92	70.6500 (0.000,0.000,0.00)
Current tax liabilities (net)	798.49	160.44	1,171.88	407.13	Net increase/(decrease) in cash and	(2 220 84)	(100.27)		012.52	2,043.31
Total current liabilities	38,396.13	23,885.18	55,470.05	41,259.83	cash equivalents	(2,229.81)	(199.27)	Exchange fluctuation on cash	0.45	(0.47
Total liabilities	56,898.37	57,253.35	85,966.07	86,146.94	Opening balance of cash and cash equivalents	11,102.75	9,362.78	and cash equivalent	0.45	
Total equity and liabilities	197,144.04	189,515.99	150,915.16	146,848.07	Closing balance of cash and cash equivalents	8,872.94	9,163.51	Closing balance of cash and cash equivalents	419.78	1,148.97

1 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016. 2 The above results were reviewed by the Audit Committee at its meeting held on 5th November, 2020 and approved by the Board of Directors at their meeting held on 6th November, 2020.

- 3 The results for the quarter and half year ended 30th September, 2020 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results. 4 Pursuant to the Taxation Laws (Amendment) Ordinance 2019 ('Ordinance') Issued by Ministry of Law and Justice (Legislative Department) on 20th September 2019 which is effective 1st April 2019, domestic companies have the option to pay corporate Income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Ordinance has subsequently been enacted as Taxation Laws (Amendment) Act, 2019. The Company upon the amendment made an assessment of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit and other exemptions. The Company has also re-measured its deferred tax liability following the clarification issued by Technical Implementation Group of Ind AS implementation Committee by applying the lower tax rate in measurement of deferred taxes only to extent that the deferred tax liabilities are expected to be reversed in the period during which it expects to be subject to lower tax rate.
- 5 The Company completed its sale of intimate hygiene brand, VWash to Hindustan Unilever Limited during the quarter ended 30th June, 2020. 6 "Exceptional item: Exceptional items in the standalone financial results for the guarter and half year ended 30th September, 2020 of Rs. 31.40 and Rs. 311.30 respectively are on account of gain from transfer of intimate hygiene brand Vwash, sale of IP assets and reimbursement of onetime costs."

The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are notified. 8 The list of subsidiaries as of 30th September, 2020 is provided in Annexure A.

9 The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.

10 As at 30th September, 2020, pursuant to Employee Stock Options Scheme 2016, 404,247 options were outstanding, which upon exercise are convertible into equivalent number of equity shares. 11 The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Group's financial results for the quarter and half year ended 30th September,

12 Diluted EPS has been computed considering the effect of conversion of ESOPs. 13 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited

List of entities included in the consolidated financial results for the quarter and half year ended 30 September 2020

1.Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2.Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) 6.Glenmark Holding S.A. 7.Glenmark Pharmaceuticals S.R.L (liquidated with effect from 30 July 2020) 8.Glenmark Pharmaceuticals Inc. 10.Glenmark Pharmaceuticals Inc. 11.Glenmark Pharmaceuticals Inc. 11.Glenmark Pharmaceuticals Inc. 12.Glenmark Pharmaceuticals Inc. 13.Glenmark Pharmaceuticals Inc. 14.Glenmark Pharmaceuticals Inc. 15.Glenmark Pharmaceuticals Inc. 15 Pharmaceuticals Peru SAC 15. Glenmark Pharmaceuticals Colombia SAS, Colombia 16. Glenmark Dominicana SRL 19. Glenmark Pharmaceuticals Egypt S.A.E. 20. Glenmark Pharmaceuticals FZE 21. Glenmark Impex L.L.C 22. Glenmark Philippines Inc. 23. Glenmark Pharmaceuticals (Nigeria) Ltd 24. Glenmark Pharmaceuticals (Australia) Pty Ltd 27. Glenmark Pharmaceuticals South Africa (pty) Ltd 28. Glenmark Pharmaceuticals (Thailand) Co. Ltd 29.Glenmark Pharmaceuticals B.V. 30.Glenmark Pharmaceuticals Canada Inc. 32.Glenmark Pharmaceuticals Canada Inc. 32.Glenmark Pharmaceuticals Kenya Ltd 33.Glenmark Pharmaceuticals Kenya Ltd 33.Glenmark Pharmaceuticals Canada Inc. 32.Glenmark Pharmaceuticals Canada Inc. 32.Glenma 36. Glenmark Pharmaceuticals Distribution s.r.o. 37. Glenmark Pharmaceuticals Nordic AB 38. Glenmark Pharmaceuticals Singapore Pte. Ltd. 41. Ichnos Sciences Biotherapeutics SA (Formerly known as Glenmark Biotherapeutics SA) 42.Ichnos Sciences Inc., USA (w.e.f. 31 May, 2019) 43.Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited) 44.Glenmark Distribuidora De Medicamentos E Produtos Cosmeticos Ltda. (w.e.f. 20 March 2020)

For and on behalf of the Board of Directors

Glenn Saldanha Chairman & Managing Director

Mumbai, November 6, 2020